X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/03/28/2853678/0/en/HUTCHMED-Announces-Savolitinib-sNDA-Accepted-in-China-for-Treatment-Na%C3%AFve-or-Previously-Treated-Patients-with-Locally-Advanced-or-Metastatic-MET-Exon-14-NSCLC.html
https://www.globenewswire.com//news-release/2023/09/12/2741334/0/en/HUTCHMED-Highlights-Presentation-of-Results-from-the-Phase-IIIb-Trial-of-Savolitinib-at-the-2023-World-Conference-of-Lung-Cancer.html
https://www.hutch-med.com/savolitinib-china-breakthrough-therapy-designation-for-gastric-cancer/
https://www.globenewswire.com/news-release/2023/08/29/2733012/0/en/HUTCHMED-Receives-Breakthrough-Therapy-Designation-in-China-for-Savolitinib-for-Gastric-Cancer.html
https://www.globenewswire.com/news-release/2023/04/04/2640347/0/en/HUTCHMED-Initiates-Registration-Phase-Enrollments-of-HMPL-453-for-IHCC-and-Savolitinib-for-Gastric-Cancer-following-NMPA-Consultations.html
https://www.quotientsciences.com/news/quotient-sciences-contributes-clinical-pharmacology-drug-development-article-phase-1-study
http://www.pharmafile.com/news/722650/tagrisso-combined-hutchmed-drug-clears-lung-cancer-test
https://www.globenewswire.com/news-release/2022/08/08/2493638/0/en/HUTCHMED-and-AstraZeneca-Announce-that-TAGRISSO-Plus-Savolitinib-Demonstrated-49-Objective-Response-Rate-in-Lung-Cancer-Patients-with-High-Levels-of-MET-Overexpression-and-or-Ampli.html
https://www.globenewswire.com/news-release/2022/07/13/2478625/0/en/HUTCHMED-Highlights-First-Presentation-of-Results-of-the-SAVANNAH-Global-Phase-II-Trial-of-Savolitinib-plus-TAGRISSO-at-the-2022-WCLC-Annual-Meeting.html
https://www.globenewswire.com/news-release/2021/11/01/2324051/0/en/HUTCHMED-and-AstraZeneca-Initiate-SAMETA-Global-Phase-III-Trial-of-Savolitinib-in-Combination-with-PD-L1-Inhibitor-IMFINZI-in-Patients-with-MET-Driven-Advanced-Papillary-Renal-Cell.html
https://www.globenewswire.com/news-release/2021/09/08/2293176/0/en/HUTCHMED-and-AstraZeneca-Initiate-SANOVO-Phase-III-Trial-of-ORPATHYS-and-TAGRISSO-Combination-as-a-First-Line-Therapy-for-Certain-Lung-Cancer-Patients-in-China.html
https://www.fiercebiotech.com/research/could-anti-cancer-gene-p53-be-a-target-treating-kidney-cancer
https://www.biospace.com/article/releases/chi-med-highlights-publication-of-phase-ii-data-showing-promising-efficacy-for-savolitinib-in-met-amplified-gastric-cancers/?s=95
https://endpts.com/chi-med-cuts-surufatinib-phiii-short-fda-greenlights-herceptin-copycat-from-amgen-allergan/
http://www.pharmatimes.com/news/savolitinib_found_to_help_treatment-resistant_lung_cancer_in_combo_with_azs_tagrisso_1283228
https://www.fiercepharma.com/pharma/chi-med-astrazeneca-s-savolitinib-helps-some-tagrisso-resistant-egfr-lung-cancer-patients
Market Place
Share 
